Tg(INSR)2Ebna

A transgenic construct was engineered to contain human insulin receptor sequence modified to contain a lysine to methionine missense mutation at codon 1030. The substitution of lysine 1030 with methionine is expected to disrupt the putative ATP binding site, thereby eliminating the tyrosine kinase activity of the protein. A 1.5 kb region of the human insulin receptor (INSR) promoter was included to direct expression in a variety of tissues. The expression of the human transcript in transgenic mice was verified by Northern blot analysis. (J:80642)